AI Article Synopsis

  • Antipsychotics are frequently used to manage behavioral and psychological symptoms in older adults with dementia, but they carry risks such as increased mortality and stroke.
  • A study analyzed long-term care data from a suburban Japanese city to assess the prevalence and factors influencing antipsychotic use among older adults with dementia.
  • The results showed a prevalence of 10.7% for antipsychotics in those with probable dementia, with higher use linked to lower cognitive function, use of antidementia drugs, and institutional care, while older age correlated with lower odds of use.*

Article Abstract

Objectives: Antipsychotics are used to manage the behavioral and psychological symptoms of dementia (BPSD), despite their association with greater risks for mortality and cerebrovascular events. Previous studies in Japan have estimated the prevalence of antipsychotics among older adults who took antidementia drugs. Using long-term care (LTC) data, we aimed to obtain more accurate estimates of the prevalence of antipsychotics and to determine factors related to their use in older adults with dementia.

Methods: Medical and LTC claims data and LTC certification data between April 2012 and September 2013 were obtained from a middle-sized suburban city. The 1-year prevalence of antipsychotic use was estimated among individuals with probable dementia aged greater than or equal to 75 years who were prescribed antidementia drugs and/or had dementia based on LTC needs certification data.

Results: Of 25 919 participants, 4865 had probable dementia and 1506 were prescribed antidementia drugs. The prevalence of antipsychotics among participants with probable dementia was 10.7%, which was lower than that in those who were prescribed antidementia drugs (16.4%). Among participants with probable dementia with LTC certification data available (N = 4419), lower cognitive function (vs mild; adjusted odds ratio 2.16, 95% confidence interval 1.63-2.86), antidementia drug use (2.27, 1.84-2.81), and institutional LTC services use (2.34, 1.85-2.97) were associated with greater odds of antipsychotic use, whereas older age (greater than or equal to 92 years) was associated with lower odds (vs less than 77 years; 0.42, 0.27-0.65).

Conclusions: These findings may be useful for estimating the burden of BPSD and for taking measures to reduce inappropriate antipsychotic prescription.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590349PMC
http://dx.doi.org/10.1002/gps.5041DOI Listing

Publication Analysis

Top Keywords

antidementia drugs
16
probable dementia
16
prevalence antipsychotics
12
ltc certification
12
prescribed antidementia
12
dementia aged
8
long-term care
8
older adults
8
certification data
8
greater equal
8

Similar Publications

Article Synopsis
  • Plant extracts are complex mixtures, and this complexity challenges scientists in pharmacological and clinical research, particularly with ginkgo biloba leaf extract.
  • A narrative review highlights ginkgo biloba's composition and clinical evidence for treating Alzheimer's disease, noting its approval as a medicinal product in various regions.
  • While ginkgo biloba extract EGb 761 is well-researched and shows promise against cognitive decline, its exact mechanism of action remains unclear, and clinical study results vary.
View Article and Find Full Text PDF
Article Synopsis
  • Delirium is a problem that often affects older people in hospitals, and it might increase the chances of them getting dementia later on.
  • A study looked at over 261,000 patients in Osaka to see how delirium during hospital stays is related to the development of dementia.
  • The results showed that people who experienced delirium had dementia show up much faster compared to those who didn't, highlighting the need to prevent delirium and watch for cognitive decline in these patients.
View Article and Find Full Text PDF

Longitudinal associations between exercise and biomarkers in autosomal dominant Alzheimer's disease.

Alzheimers Dement

November 2024

Centre for Healthy Ageing, Health Futures Institute, Murdoch University, Murdoch, Western Australia, Australia.

Introduction: We investigated longitudinal associations between self-reported exercise and Alzheimer's disease (AD)-related biomarkers in individuals with autosomal dominant AD (ADAD) mutations.

Methods: Participants were 308 ADAD mutation carriers aged 39.7 ± 10.

View Article and Find Full Text PDF

Background: Antipsychotic and other psychotropic medication use is prevalent among community-dwelling older adults with dementia despite the potential for adverse effects. Two Centers for Medicare & Medicaid Services (CMS) initiatives, the National Partnership to Improve Dementia Care ("the Partnership") and the Five Star Quality Rating System for antipsychotic use reporting, have been successful in reducing antipsychotic use in nursing home residents. We assessed if these initiatives had a spillover effect in antipsychotic and other psychotropic medication use among community dwellers with dementia due to potential overlap in prescribers across settings.

View Article and Find Full Text PDF

Antidementia and Psychotropic Drug Use in Older People with Dementia in Australia: A National Data Linkage Study.

J Am Med Dir Assoc

November 2024

The University of Sydney, School of Pharmacy, Faculty of Medicine and Health, Sydney, New South Wales, Australia; Kolling Institute, The University of Sydney Faculty of Medicine and Health, Northern Clinical School and Northern Sydney Local Health District, Royal North Shore Hospital, St Leonards, New South Wales, Australia; Pharmaceutical Policy Node, Charles Perkins Centre, The University of Sydney, New South Wales, Australia. Electronic address:

Objectives: To estimate the national prevalence of antidementia and psychotropic medication use, and sociodemographic factors associated with their use, in Australians living with dementia.

Design: Retrospective cross-sectional study.

Setting And Participants: Nationwide data linkage study using 2021 Census and Pharmaceutical Benefits Scheme (PBS) data.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!